๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Neoplasms
Clinical trial register · China

Breast Neoplasms Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 4 Changsha 3 Anyang 2 Changchun 2 Changde 2
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing4 Changsha3 Anyang2 Changchun2 Changde2
All 19 locations
Target enrolment
to

Breast Neoplasms trials in China

8 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
NCT07174336Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
800
Anyang, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang, Fuzhou
2025-12-22
Recruiting
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms, Colorectal Neoplasms
Eli Lilly and Company
Phase 1
241
Shanghai
2025-10-22
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Beijing, Tianjin
2025-08-06
Active, closed
A Study of LY3484356 in Chinese Participants With Advanced Breast Cancer
NCT05509790Breast Neoplasms
Eli Lilly and Company
Phase 1
17
Wuhu, Changsha, Nanchang, Shanghai
2022-10-09
Active, closed
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT05514054Breast Neoplasms
Eli Lilly and Company
Phase 3
8,000
Anyang, Baoding, Beijing, Changchun, Changde, Changsha, Chengdu, Deyang
2022-10-04
Active, closed
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308Breast Neoplasms, Neoplasm Metastasis
Eli Lilly and Company
Phase 3
874
Bengbu, Beijing, Fuzhou, Guangzhou, Jiangmen, Shenzhen, Zhanjiang, Zhongshan
2021-10-04
Rows per page Showing 1–8 of 8
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/breast-neoplasms

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 8 of those studies listing the condition Breast Neoplasms that also match the filters currently applied.

How many Breast Neoplasms trials are recruiting in China?

4 of the 8 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Neoplasms), 8 studies
PhaseStudiesRecruitingShare
Phase 34150%
Phase 13237.5%
Phase 21112.5%

Most active sponsors

Lead sponsors with the most studies (Breast Neoplasms)
Lead sponsorStudiesRecruiting
Eli Lilly and Company84
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.